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Abstract: When a patient with lung cancer presents non-specific respiratory symptoms there are many diagnostic options. 
Chemotherapy is the cornerstone of treatment in many stages of lung cancer and its toxicity is well known. The main pri-
ority is to prevent life-threatening diseases such as lung infection, which can be treated successfully if a prompt, accurate 
diagnosis is given. Drug-induced pulmonary disease must be avoided at all costs but it is also important to avoid side-
effects of drugs which do not directly interfere with respiratory physiology but may impair gas exchange. This review 
highlights the risks and characteristics of non-cytostatic-induced lung toxicity caused by agents that have been commonly 
used to treat cancer in recent decades. Physicians should be alert to the possibility of this neglected non-chemotherapy-
induced lung toxicity in cancer patients, since early withdrawal of the offending drug is mandatory. 
Keywords: Non-chemotherapy-induced lung toxicity, administration route toxicity, lung injury, cancer treatment toxicity. 
1. INTRODUCTION 
  Since the first report of a link between busulfan and pul-
monary toxicity was published in 1961 [1], the literature on 
lung disease induced by cytotoxic drugs has grown steadily 
[2]. As the number of drugs used in cancer chemotherapy 
increases, the incidence of pulmonary toxic effects may rise 
even further, especially since patients with cancer now sur-
vive longer and their lung cell populations are exposed to 
cytotoxic agents for longer periods of time. 
  Oncologists often have to consider a broad differential 
diagnosis when lung cancer patients under cytostatic treat 
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ment present non-specific respiratory symptoms and radio-
graphic shadowing [3-5]. Because of their prognostic and 
therapeutic implications the following etiologies should be 
assessed first in the initial diagnostic approach: lung infec-
tion, caused either by conventional pathogens or by atypical 
microorganisms, malignancy-related thromboembolic pul-
monary disease, local tumor progression, iatrogenic intra-
alveolar hemorrhage, radiotherapy-induced adverse effects, 
transfusion reactions, postoperative complications in patients 
who have undergone thoracic surgery, oxygen toxicity, and 
finally drug-induced pulmonary toxicity. In this last case, 
most patients are receiving a wide array of drugs other than 
cytostatics which may cause lung toxicity [6]. Once the cli-
nician has raised the suspicion of drug toxicity, the classic 
criteria proposed by Karch and Lasagna [7] should be ap-
plied so as to ensure accurate diagnosis (Table 1). 
Table 1. Assessment of Link Between Agent and Event
* 
 
  Definite Probable Possible  Conditional 
Appropriate temporal sequence   Yes Yes Yes Yes 
Known reaction to agent  Yes Yes Yes  No 
Improved with dechallenge
1  Yes Yes  Yes-No  No 
Relapse on rechallenge
2  Yes ?  ?  ? 
Event reasonably explained by clicinal state or other therapies  No No Yes No 
*Modified from Karch and Lasagna [7]. 
1The effects of stopping the drug or reducing the dose. 
2Relapse of the effects after restarting the drug. 2    The Open Respiratory Medicine Journal, 2007, Volume 1  Domingo and Roig 
  The aim of this article is to review the other frequently 
neglected side-effects of cancer treatment in which the drugs 
involved do not interfere with parenchymal lung physiology 
but may eventually have repercussions on gas exchange. 
2. METHODOLOGY 
  First we undertook a large-scale review of pulmonary 
toxicity caused by cytotoxic drugs [2] and selected the che-
motherapeutic drugs responsible for respiratory disturbances 
not related to their cytotoxic effect. We then reviewed the 
different non-cytotoxic drugs currently used to treat malig-
nancies, and selected those with potential lung toxicity. Fi-
nally, we examined the side-effects related to the administra-
tion route used. We searched the PubMed database for all 
prospective and retrospective studies reporting these items 
and referenced those providing relevant information. 
  The paper is divided into three sections. In the first we 
discuss the mechanisms of how chemotherapy indirectly 
causing parenchymal lung toxicity may eventually alter res-
piratory function (Table 2); in the second we refer to the 
pulmonary toxicity caused by non-cytotoxic drugs used in 
the treatment of malignancies (Table 3) associated with the 
administration of the chemotherapy protocol. In the third, we 
consider the side-effects due to the drug administration route 
(Table 4). 
Table 2.  Mechanisms of Respiratory Impairment Caused by 
Chemotherapy Indirectly Causing Parenchymal 
Lung Toxicity 
 
  Respiratory muscle impairment 
  Acute encephalopathy 
  Non-cardiogenic pulmonary edema. 
  Pleural effusion 
 
 
Table  3.  Non-Cytotoxic Drugs Used for the Treatment of 
Malignancies 
 
  Granulocyte colony-stimulating factor (G-CSF) 
  Monoclonal antibodies 
  All-trans retinoic acid 
  Drugs favouring deep venous thrombosis/pulmonary embolism:  
Erythropoietin 
Megestrol acetate 
Thalidomide 
  Epidermal growth factor receptor tyrosine kinase inhibitors: 
Gefitinib 
Erlotinib 
 
 
Table 4.  Side-Effects Due to Drug Administration Route 
 
  Bronchial artery infusion of cytostatic drugs 
  Intrathoracic extravasation of cytostatics 
  Venous thromboembolism associated to central venous catheters 
 
3. SIDE-EFFECTS OF CHEMOTHERAPY INDI-
RECTLY CAUSING PARENCHYMAL LUNG TOXIC-
ITY 
3.1. Respiratory Muscle Impairment 
  Procarbazine, cytarabine, chlorambucil and above all 
vincristine may cause neuropathies which can affect respira-
tory muscle function [8]. The primary manifestations are 
usually sensory, but drug-induced motor or sensorimotor 
neuropathies also occur, most commonly caused by vincris-
tine. Most of these case are mild or even subclinical symmet-
ric distal neuropathies. It is not clear whether the respiratory 
muscles are ever involved, though some of the many cases of 
idiopathic phrenic nerve palsies are likely to be drug-induced 
[9]. The pathogenic mechanism seems to be neurotubular 
damage. This adverse event may be particularly serious 
when anesthesia is administered to these patients [10]. 
3.2. Acute Encephalopathy and Respiratory Depression 
(Ifosfamide and Methotrexate) 
  This side-effect merits special attention, given the high 
prevalence of chronic obstructive lung disease and sleep ap-
nea-hypopnea syndrome. Both entities can cause chronic 
hypercapnia which may deteriorate with the addition of an 
extra offending agent that favors respiratory depression [8]. 
  Direct pulmonary toxicity due to ifosfamide is very rare 
but possible [11]. The risk of CNS depression following ifos-
famide therapy (about 12%)
 [12-13] should be considered in 
patients with advanced chronic obstructive lung disease, a 
common association in lung cancer, since somnolence may 
worsen hypercapnia and enhance encephalopathy. Caution is 
also needed in the case of underlying central or obstructive 
sleep apnea syndrome, since its prevalence in the general 
population is relatively high. 
  Methotrexate (MTX) is a cell cycle-specific agent that 
inhibits the enzyme
 dihydrofolate reductase, preventing the 
conversion of folic
 acid to tetrahydrofolic acid and inhibiting 
cell replication. MTX crosses the blood-brain barrier and can 
be administered
 intravenously and via an intrathecal route to 
eradicate leukemic
 cells from the CNS and prevent CNS re-
currence. This is why chemotherapeutic regimens include 
methotrexate for acute lymphocytic leukemia treatment. 
Both high-dose intravenous MTX and intrathecal MTX are
 
associated with demyelination, white matter necrosis, loss of
 
oligodendroglia, axonal swelling, microcystic encephalo-
malacia,
 and atrophy relatively selective for the deep cerebral 
white
 matter. A diminished choline-to-creatine ratio has been
 
reported in children with MTX-related neurotoxicity; this 
may
 be related to disturbances of myelin metabolism or inhi-
bition
 of glucose metabolism induced by MTX [14]. 
  Acute MTX neurotoxicity usually results in
  stroke-like 
symptoms, such as aphasia, weakness, sensory deficits,
 
ataxia, and seizures. Several cases of MTX-induced acute 
encephalopathy have been reported [15-19], presenting with 
confusion and even coma with high-dose methotrexate ther-
apy. As with ifosfamide, clinicians should bear in mind the 
possibility of respiratory compromise in severe COPD. 
3.3. Non-Cardiogenic Pulmonary Edema 
  Non-cardiogenic pulmonary edema may be caused by 
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toxicity due to intrathecal methotrexate may be the cause 
[20-21].  Less frequently, this methotrexate administration 
route has been associated with interstitial pneumonitis [22]. 
Non-cardiogenic pulmonary edema may also be the result of 
increased permeability. This has been reported with IL-2 
infusions as well as with docetaxel [23]. Sirolimus (previ-
ously called rapamycin) is a macrolide antibiotic isolated 
from the fungus Streptomyces hygroscopicus. It has potent 
anticandida activity, but subsequent studies have revealed 
impressive antitumor and immunosuppressive activities as 
well [24]. The drug is used to prevent rejection of organs and 
bone marrow transplants and is also under investigation as a 
treatment for cancer. Among its side-effects, pulmonary 
edema or distress syndrome have occasionally been de-
scribed [25]. 
3.4. Pleural Effusion 
  Docetaxel may cause pleural effusion by increasing per-
meability. However, although large effusions may cause 
severe respiratory compromise, some authors do not consider 
this to be a classic pulmonary toxicity. Occasionally, 
methotrexate has also been found to cause pleurisy [26]. 
4. PULMONARY TOXICITY DUE TO NON-CYTOTO-
XIC DRUGS USED TO TREAT MALIGNANCIES 
  Many non-cytotoxic drugs can cause pulmonary toxicity. 
In this section we mention three groups of drugs, the first 
two of which are widely prescribed in cancer patients. We 
use the common toxicity criteria grading [27]. 
4.1. Granulocyte Colony-Stimulating Factor (G-CSF) 
  These drugs are frequently prescribed to hasten recovery 
from cancer chemotherapy-induced neutropenia. Some have 
been reported to induce pulmonary edema. Pegfilgrastim is a 
long-acting G-CSF, recently approved by the Food and Drug 
Administration [28],  and lenograstim is the glycosylated 
recombinant form of human granulocyte colony stimulating 
factor [29]. 
4.2. Monoclonal Antibodies 
  Monoclonal antibodies are a new class of non-cytotoxic 
agents targeted at specific receptors on cancer cells. In addi-
tion to their direct cellular effects, antibodies can carry sub-
stances such as radioactive isotopes, toxins, and antineoplas-
tic agents to the targeted cells. Five monoclonal antibodies-
rituximab, trastuzumab, gemtuzumab ozogamicin, alemtu-
zumab, and ibritumomab tiuxetan -- are available for clinical 
use. Monoclonal antibodies currently under study include 
edrecolomab and tositumomab [30-31]. 
  Trastuzumab is a humanized anti-HER2 mAB which 
achieves response rates of 15-40% when used as a single 
agent in patients with metastatic HER2-overexpressing 
breast cancer, and prolongs survival when added to chemo-
therapy in first line therapy in these patients [32]. The major 
side-effects include pulmonary [33] and cardiac toxicity. 
Fleming et al. [32]. treated 45 patients with trastuzumab and 
IL2, a regimen that is no longer given today; grade 3 pulmo-
nary toxicity or higher was found in five patients and attrib-
uted to intermediate-dose IL2 in three. Of the seven grade 2 
pulmonary toxicities, six occurred in 21 patients known to 
have lung metastasis Several trastuzumab first-dose infusion-
related reactions with pulmonary components were also 
found. Byrd et al. [34] observed that the five patients they 
treated with trastuzumab developed severe pulmonary infu-
sion-related toxicity. Occasionally, organizing pneumonia 
has also been attributed to trastuzumab [35]. 
  Rituximab is also known to cause pulmonary dysfunc-
tion, though probably less frequently than trastuzumab. Al-
veolar hemorrhage [36], acute pneumonitis and pulmonary 
fibrosis have been observed [37-40]. Very occasionally, a 
desquamative alveolitis is also found [41]. 
 Recently,  Biehn  et al. [42] reported the first case of bron-
chiolitis obliterans organizing pneumonia caused by rituxi-
mab. However, lung toxicity seems to be quite rare. In a re-
cent study, Kanelli et al. [43] observed only one case of tox-
icity in a cohort of 27 patients. 
  Gemtuzumab ozogamicin was approved in 2000 by the 
FDA. Its major side-effect is hepatotoxicity (31% of patients 
show abnormal liver enzymes) but adult respiratory distress 
syndrome (ARDS) has also been reported [44]. Alentuzumab 
causes immunosuppression, increasing the risk of infections 
[31] and possibly ARDS [45]. Novel monoclonal antibodies 
such as tositumomab, edrecolomab and cetuximab appear 
promising but are still under evaluation [46-49]. 
4.3. All-Trans Retinoic Acid 
  Retinoids are natural or synthetic derivatives of vitamin 
A. All-trans retinoic acid has clinical applications in acute 
promyelocytic leukemia. More than half the patients treated 
with this drug experience retinoic acid syndrome, a disorder 
characterized by fluid retention, weight gain, respiratory 
distress, radiographic pulmonary infiltrates, hectic fever and 
pleural or pericardial effusion [50]. 
4.4. New Iatrogenic Risk Factors for Deep Venous 
Thrombosis and/or Pulmonary Embolism 
  It has long been recognized that patients with malignan-
cies have an increased risk of thromboembolism [51], some-
times preceding cancer diagnosis or, more commonly, as 
complications. In addition to the well-known risk factors 
such as chemotherapy, hormonal therapy and tumor type and 
stage, other therapeutic strategies have been added to the list 
of risk factors for developing deep venous thrombosis and/or 
pulmonary embolism. 
4.4.1. Erythropoietin 
 Erythropoietin  is the primary hematopoietic growth fac-
tor for erythropoiesis. It has proved effective in increasing 
hemoglobin levels in the majority of patients with cancer and 
anemia [52-53]. Erythropoietin may contribute synergically 
to thrombosis in this setting by increasing red cell mass and 
thus whole blood viscosity. It also results in reticulocytosis, 
which raises the proportion of young metabolically active 
red blood cells, thus increasing platelet reactivity in vitro. 
The drug has also been found to be synergistic with the 
platelet growth factor thrombopoietin for platelet activation 
and is associated with increased platelet reactivity and endo-
thelial activation. Recent findings suggest that platelet-red 
cell interactions play a role in venous thrombosis. Taken 
together, these data suggest that erythropoietin may be 
thrombogenic. In a retrospective case-control study under-
taken in 147 patients with carcinoma of the uterine, cervix or 
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found symptomatic thromboembolic disorders in 23%. Pa-
tients treated with recombinant human erythropoietin were 
10 times more likely to develop a thrombosis than non-
treated patients. Dusembery et al. also reported a rate of 20% 
(four out of twenty patients) [55]. 
4.4.2. Megestrol Acetate 
  This drug is a progestational agent which is currently 
used as an appetite stimulant in patients suffering from can-
cer anorexia/cachexia syndrome [56-57]. In a retrospective 
review, Bolen et al. [58] found that more than 30% of their 
18 nursing home residents treated with megestrol developed 
deep venous thrombosis. The controversy in the literature is 
evident since the results of Oberhoff et al. [59] did not pro-
vide any evidence of a thrombotic effect of high-dosage 
megestrol acetate amongst patients with advanced gyneco-
logical malignancies. These authors concluded that the in-
crease in the incidence of thrombosis observed in other re-
ports may be the consequence of other risk factors such as 
tumour-induced hypercoagulability, simultaneous chemo-
therapy or other individual thrombosis risk factors. The 
treatment appears to have been used safely in other studies 
[56-57]. 
4.4.3. Thalidomide 
  Thalidomide is a glutamic acid derivative drug with 
antiangiogenic and tumor necrosis factor (TNF) blocking 
agent properties that result in anti-inflammatory and immu-
nodepressive effects. The drug is considered an adjuvant 
immunosuppressant [60]. Since increased bone marrow vas-
cularity has a poor prognosis in myeloma, the efficacy of 
thalidomide has been evaluated in patients with refractory 
disease by several research groups [61-62]. Common side-
effects of thalidomide are mild, dose-related and reversible 
and include constipation, fatigue, paresthesias and dry skin. 
More rarely, the drug has been found to be associated with 
an increased risk of thromboembolism when used in patients 
with malignancy [63]. Although single-agent thalidomide 
has minimal prothrombogenic activity, its combination with 
cytotoxic chemotherapy is associated with a significant in-
crease in the risk of deep venous thrombosis [64]. Current 
recommendations are that clinicians consider using long-
term aspirin [65] or even coumarin concomitantly with tha-
lidomide in this situation. According to Baz et al. 65] daily 
low-dose aspirin (81 mg) administered orally reduced the 
incidence of vascular thrombosis without increasing bleeding 
complications. Moreover, Scarpace et al. [66] also reported 
that two out of four patients who developed arterial throm-
boses treated with thalidomide were receiving concomitant 
anticoagulation with aspirin and warfarin. Finally, since 
erythropoietin increases the risk of vascular thrombosis, it 
could be argued that the concomitant use of this drug and 
thalidomide could have an additive effect on hypercoagula-
bility, but according to Galli et al. [67] erythropoietin does 
not seem to increase the risk of thrombosis in myeloma pa-
tients receiving thalidomide. 
4.5. Epidermal Growth Factor Receptor Tyrosine Kinase 
Inhibitors (Gefitinib and Erlotinib) 
  Recent advances in cancer biology have led to the identi-
fication of several potential molecular targets that play a key 
role in cancer development and progression. Selective target-
ing of cancer cells on the basis of their molecular phenotype 
can provide effective anticancer activity, avoiding the side 
effects commonly induced by cytotoxic chemotherapy. 
Among these targets, the epidermal growth factor receptor 
(EGFR) has been widely investigated in different human 
malignancies due to its critical role in cancer proliferation 
and survival. The epidermal growth factor receptor (EGFR) 
is involved in cancer progression and development and, be-
ing overexpressed in a variety of human malignancies, is an 
attractive target for selective anticancer therapy. EGFR tyro-
sine kinase inhibitors (TKIs) produce dramatic and durable 
responses in a fraction of non-small cell lung cancer patients 
[68-69]. 
  Lung toxicity related to this tyrosine kinase activity in-
hibitor is very uncommon and usually mild [70]. Worldwide, 
the incidence of interstitial lung disease is <1% [2]. How-
ever, severe pulmonary reactions have also been reported 
[71]. 
5. SIDE-EFFECTS DUE TO DRUG ADMINISTRA-
TION ROUTE 
5.1. Bronchial Artery Infusion of Cytostatic Drugs 
  Though not a new therapy, the effectiveness of the infu-
sion of cytotoxic drugs into the bronchial artery has been 
reconsidered during the past decade for treatment of central 
advanced and early staged lung cancer [72] as well as for 
lung metastasis, although the instances reported in the latter 
case are fewer [73]. Though the technique allows the infu-
sion of high-density chemotherapeutics into objective limited 
lesions [72] side-effects are not eliminated. In their study, 
Osaki et al. [72] treated seven patients, three of whom sub-
sequently presented severe bronchial ulcers and one of 
whom died of pulmonary hemorrhage. Suzuki et al. [73] 
recently reported a massive hemoptysis from a bronchial 
pulmonary arterial fistula in a patient with lung metastasis. 
Lung hemorrhages usually occur between one and three 
months after bronchial artery infusion. Other side-effects 
include esophageal ulceration, spinal cord damage, and 
bronchial esophageal fistulas. 
5.2. Intrathoracic Extravasation of Cytostatics 
  Most extravasation accidents involve the limbs However 
few data are available regarding intrathoracic extravasation 
of cytostatic agents administered in central venous lines. To 
date, only seven cases have been reported [74], in one child 
and six adults. In three cases the perforations were acute and 
were entirely procedure-related. Pain and fever were the 
prominent symptoms and leukocytosis was present in three 
patients. Computed tomography chest scan was the diagnos-
tic method used. Late perforations may be related to an in-
creased concentration of cytostatics due to elevated venous 
pressure which may favor the erosion of the vessel wall. Al-
though there is no commonly accepted treatment at present, 
the standard administration of dalteparin/warfarin can allow 
the central line to remain in situ with little risk of line failure 
or recurrence/extension of the DVT [75]. Recent guidelines 
do not recommend antithrombotic prophylaxis (AP) to pre-
vent catheter-related thrombosis in cancer patients with a 
central line. In their study, Fagnani et al. observed no differ-
ence in catheter-related thrombosis in patients given AP or 
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boembolism (including deep and superficial thromboses and 
pulmonary embolism) was less frequent with AP (4% versus 
8.2%), mortality was also lower (25% versus 44%, but only 
advanced cancer, not AP, was found to be significantly asso-
ciated with mortality. No major bleeding was recorded with 
AP. So current AP schedules do not appear to prevent cathe-
ter-related thrombosis. Systemic venous thromboembolism 
and patients’ mortality, however, appeared lower after pro-
phylaxis [76]. 
5.3. Venous Thromboembolism Associated to Central 
Venous Catheters 
  The first long-term central venous catheter (CVC) was 
introduced in 1973 by Boviac for parenteral nutrition. In the 
early 1980s, totally implantable port systems were intro-
duced in clinical practice. Among early pulmonary compli-
cations are pneumothorax, hemothorax and air embolism 
(estimated rate ranging between 0.3% and 12%) [77]. CVC-
related deep venous thrombosis are among late complica-
tions. The reported incidence of symptomatic catheter-
related deep venous thrombosis in adults varies from 0.3% to 
28% while the incidence of venographically demonstrated 
thrombosis ranges between 27 and 66%. The incidence with 
subcutaneous ports seems to be lower, around 1% (2 out of 
175 patients [78-79]. 
CONCLUSIONS 
  Respiratory toxicity other than the classical chemother-
apy-induced lung toxicity may have a substantial impact on 
the prognosis of cancer patients. Frequently, withdrawal of 
the drug will ensure recovery. Though in general the inci-
dence of this type of toxicity is low, oncologists should be 
aware of its existence; if it remains unrecognized, the likeli-
hood of a fatal outcome is substantially increased. 
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